CRIS Current Research Information System

LOLLINI, PIER LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.270
EU - Europa 8.306
AS - Asia 7.727
AF - Africa 545
SA - Sud America 529
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 7
Totale 27.399
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.120
IT - Italia 2.573
CN - Cina 2.422
SG - Singapore 2.143
GB - Regno Unito 1.693
VN - Vietnam 1.664
DE - Germania 965
SE - Svezia 614
HK - Hong Kong 595
UA - Ucraina 392
RU - Federazione Russa 383
IN - India 371
BR - Brasile 357
FR - Francia 322
CH - Svizzera 291
IE - Irlanda 251
NL - Olanda 245
CI - Costa d'Avorio 201
KR - Corea 184
ZA - Sudafrica 142
JP - Giappone 128
EE - Estonia 121
TG - Togo 93
CA - Canada 92
FI - Finlandia 90
BG - Bulgaria 66
ID - Indonesia 57
CO - Colombia 53
AR - Argentina 52
BE - Belgio 51
SC - Seychelles 46
JO - Giordania 42
MX - Messico 41
PL - Polonia 38
RO - Romania 34
AT - Austria 33
GR - Grecia 27
LU - Lussemburgo 26
NG - Nigeria 26
ES - Italia 21
CL - Cile 20
TR - Turchia 20
LT - Lituania 19
EC - Ecuador 18
EG - Egitto 16
IR - Iran 14
AU - Australia 13
PE - Perù 13
HR - Croazia 11
IQ - Iraq 11
PK - Pakistan 11
BD - Bangladesh 10
DK - Danimarca 9
CR - Costa Rica 7
MA - Marocco 7
AE - Emirati Arabi Uniti 6
MY - Malesia 6
VE - Venezuela 6
AL - Albania 5
AZ - Azerbaigian 5
LB - Libano 5
MD - Moldavia 5
UZ - Uzbekistan 5
DZ - Algeria 4
EU - Europa 4
PY - Paraguay 4
RS - Serbia 4
UY - Uruguay 4
CZ - Repubblica Ceca 3
HN - Honduras 3
IL - Israele 3
KH - Cambogia 3
SA - Arabia Saudita 3
TN - Tunisia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
JM - Giamaica 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LI - Liechtenstein 2
LV - Lettonia 2
MN - Mongolia 2
PH - Filippine 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TJ - Tagikistan 2
TW - Taiwan 2
YE - Yemen 2
A1 - Anonimo 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BY - Bielorussia 1
GI - Gibilterra 1
GM - Gambi 1
GT - Guatemala 1
MK - Macedonia 1
Totale 27.389
Salva come PNG Salva come JPEG
Città #
Southend 1.447
Singapore 1.404
Fairfield 1.209
Ashburn 1.039
Chandler 880
Hong Kong 589
Houston 578
Woodbridge 561
Wilmington 546
Bologna 507
Seattle 495
Hefei 489
Ann Arbor 451
Cambridge 387
Dong Ket 365
Princeton 359
Santa Clara 325
Ho Chi Minh City 309
Beijing 287
Jacksonville 256
Bern 253
Dublin 248
Boardman 242
Hanoi 242
Abidjan 201
Shanghai 196
Seoul 177
Milan 167
Nanjing 150
Dallas 148
Westminster 147
Padova 141
Los Angeles 136
Tokyo 121
Berlin 111
Frankfurt am Main 108
Lomé 93
Rome 92
Buffalo 88
Jinan 85
Turin 77
Bremen 76
Shenyang 76
Saint Petersburg 73
San Diego 70
Sofia 65
Guangzhou 61
Changsha 59
Nanchang 55
Mülheim 54
Helsinki 53
New York 53
Redwood City 52
Redondo Beach 51
Brussels 49
Hebei 47
Tianjin 45
Bengaluru 44
Jakarta 44
São Paulo 42
Amman 41
Falkenstein 40
Jiaxing 40
Redmond 40
London 39
Amsterdam 38
Medford 38
Falls Church 36
Casalecchio di Reno 35
Phoenix 34
Des Moines 33
Zhengzhou 31
Council Bluffs 30
Naples 30
Toronto 30
Verona 30
Mahé 29
Ottawa 28
Warsaw 27
Biên Hòa 26
Haikou 26
Lappeenranta 26
Yubileyny 26
Florence 25
Haiphong 25
Luxembourg 25
Da Nang 24
Abeokuta 23
Dearborn 23
Parma 23
Fuzhou 22
Hangzhou 22
Chicago 21
Nuremberg 21
Paris 21
Taiyuan 21
Catanzaro 20
Ha Long 20
Vienna 20
Ningbo 19
Totale 17.903
Salva come PNG Salva come JPEG
Nome #
Vaccini antitumorali 937
IFN-γ and CD38 in Hyperprogressive Cancer Development 380
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 353
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 343
Terapia genica 332
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 305
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 278
Abstract 5909: IDH mutations in G2-3 conventional chondrosarcoma of bone: a mono institutional experience 248
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 242
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 240
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 226
Development of a K-edge micro CT for the study of tumor angiogenesis in small animals 223
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 223
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 221
Rethinking herpes simplex virus: the way to oncolytic agents. 214
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 213
CD99 Acts as an Oncosuppressor in Osteosarcoma. 200
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 198
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 197
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors 195
CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. 194
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape 194
Virus-like particle display of HER2 induces potent anti-cancer responses 193
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 193
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 189
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. 188
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 186
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 186
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. 184
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 183
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins 181
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) 180
ImmunoGrid: Towards agent-based simulations of the human immune system at a natural scale 178
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 176
Cancer immunoprevention: from mice to early clinical trials 175
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 175
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay 174
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. 174
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 173
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 170
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 169
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 169
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 168
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 168
Oncolytic herpes virus retargeted to HER-2. 167
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 167
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 166
Antimetastatic activity of a preventive cancer vaccine. 166
Insulin-like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing sarcoma malignancy 166
In silico modeling and in vivo efficacy of cancer preventive vaccinations 165
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 165
Herpesviruses as oncolytic agents 163
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 163
CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. 162
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 162
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 162
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 162
Immunoprevention and immunotherapy of mammary carcinoma 161
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 161
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 160
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer 159
Genetic algorithm against cancer. 158
IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience 157
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 157
Modeling the competition between lung metastases and the immune system using agents. 156
Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies. 155
Cancer vaccines: Target antigens, vaccine platforms and preclinical models 154
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 154
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 153
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 153
A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY 152
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 152
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 152
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality 151
Vaccines for tumour prevention 151
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 151
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 150
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 149
Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. 149
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 149
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 148
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 148
New target antigens for cancer immunoprevention 147
Immunological prevention of a multigene cancer syndrome 147
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research 145
null 145
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 144
The molecular basis of herpesviruses as oncolytic agents. 144
Correction to: ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis 143
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy 143
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 141
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 141
Translational immunomics of cancer prevention. 141
Molecular Imaging of EGFR: It's Time to Go Beyond Receptor Expression 141
TRAF6 regulates proliferation and differentiation of skeletal myoblasts 141
Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. 141
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 140
Engagement of CD99 activates distinct programs in Ewing sarcoma and macrophages 139
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 138
The Promise of Preventive Cancer Vaccines 138
Totale 18.623
Salva come PNG Salva come JPEG
Categoria #
all - tutte 76.671
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.671
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.035 0 0 0 0 0 155 111 264 322 188 165 830
2021/20223.446 357 118 249 170 301 209 94 247 179 224 719 579
2022/20233.856 439 451 204 502 262 268 123 202 529 152 347 377
2023/20241.494 71 166 98 152 132 181 85 271 50 98 82 108
2024/20254.336 292 542 330 277 640 260 309 189 68 309 243 877
2025/20265.489 1.110 1.102 935 813 1.075 454 0 0 0 0 0 0
Totale 28.047